# Phase 1b/2a in SLE With Budoputug

> **NCT06570434** · PHASE1,PHASE2 · WITHDRAWN · sponsor: **Tenet Medicines**

## Conditions studied

- Systemic Lupus Erythematosus
- SLE
- B Cells

## Interventions

- **DRUG:** budoprutug

## Key facts

- **NCT ID:** NCT06570434
- **Lead sponsor:** Tenet Medicines
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2025-01
- **Primary completion:** 2026-12
- **Final completion:** 2027-04
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Study was never initiated
- **Last updated:** 2024-10-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06570434

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06570434, "Phase 1b/2a in SLE With Budoputug". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06570434. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*